Metropolis Healthcare Reports Strong Q2FY27 Revenue and EBITDA Margin Growth
Metropolis Healthcare Ltd 路 Others (Uncategorized) 路 05 Oct 2026, 11:42 pm
Metropolis Healthcare Reports Strong Q2FY27 Revenue and EBITDA Margin Growth Metropolis Healthcare reported approximately 15% YoY consolidated revenue growth for Q2FY27, ending 30th Sep'26. Topline growth was primarily driven by double-digit patient and test volume increases, supported by improved realizations and an enhanced product mix. TruHealth Wellness and Specialty emerged as the fastest-growing segments during the quarter. Additionally, EBITDA margins improved meaningfully on both a YoY and QoQ basis, bolstered by operating leverage and efficiency gains. Detailed financial results remain subject to auditor review.
Original exchange filing (PDF)
More announcements from Metropolis Healthcare Ltd
- Transcript of Q2 and H1 FY27 earnings conference call held on November 04, 2026 路 10 Nov 2026
- Schedule of Analyst / Institutional Investor Meeting 路 05 Nov 2026
- Link of the audio recording of the earnings conference call held on November 04, 2026 路 04 Nov 2026
- Press Release 路 04 Nov 2026
- Investor Presentation for the quarter and half year ended September 30, 2026 路 04 Nov 2026
- Board approves Interim Dividend 路 04 Nov 2026
- Unaudited Standalone and Consolidated Financial Results for the quarter and half year ended September 30, 2026 路 04 Nov 2026
- Metropolis Healthcare Limited has submitted to the Exchange, the financial results for the period ended September 30, 2026. 路 04 Nov 2026
